Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline PLC

www.gsk.com

Latest From GlaxoSmithKline PLC

Norway's OTC Market In 2018: Sales Remain Stable As GSK Consolidates Its Leading Position

Sales of non-prescription medicines in Norway edged up by less than 1% in 2018, as GSK remained the leading player on the market and its Otrivin respiratory line maintained its position as the country's best-selling OTC brand. 
Norway Market Intelligence

QuantumMDx And Glaxo Smith Kline Partner On QC Analyzer For Cell And Gene Therapies

QuantumMDx Group Ltd has signed a deal with GlaxoSmithKline to co-develop a quality control analytics system for cell and gene therapies.

Commercial Companies

ViiV's Dovato: Treatment-Naive HIV Is Earmarked For The "Complete Regimen"

The first approval in the US of a once-daily single-tablet, two-drug regimen for treatment-naive HIV from the HIV/AIDS therapy specialist, ViiV Healthcare, suggests a shift away from three-drug regimens for HIV/AIDS could be gathering pace.

Approvals Infectious Diseases

Missed BEAT Removes Tough Sell For United Therapeutics

The Phase III failure of esuberaprost combined with Tyvaso in pulmonary arterial hypertension has prompted United Therapeutics to stop developing a therapy that was already facing an uphill battle for potentially meager returns.

Clinical Trials Research & Development
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register